Bavarian Nordic A/S (LON:0DPB)

Market Cap	1.75B -0.7%
Revenue (ttm)	804.88M +13.5%
Net Income	285.75M +118.6%
EPS	3.60 +116.3%
Shares Out	n/a
PE Ratio	6.11
Forward PE	18.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,400
Average Volume	28,791
Open	190.65
Previous Close	187.30
Day's Range	188.75 - 193.35
52-Week Range	100.05 - 273.40
Beta	1.13
RSI	48.39
Earnings Date	Mar 12, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,738
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DPB

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK